Clinical trial

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-01-20

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2026-01-20Date precision: day

Registry last updated2026-09-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumorsunresolved

MSI-H or dMMR Advanced Solid Tumorsunresolved

MSI-H/dMMR Gastric Cancerunresolved

MSI-H/dMMR Colorectal Cancerunresolved

MSI-H/dMMR Gastroesophageal-junction Cancerunresolved

Endometrial Cancerunresolved

Mismatch Repair Deficient or MSI-High Solid Tumorsunresolved

Interventions

pembrolizumab (KEYTRUDA® )DRUG

Sponsors & collaborators

Eikon Therapeuticslead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 Los AngelesCalifornia, United States1 MadridSpain1 BarcelonaSpain1 HamburgGermany1 BrusselsBelgium1 KrakowPoland1 LodzPoland1 Fort WorthTexas, United States1 LisbonPortugal1 HialeahFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07262619 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.